Iovance Biotherapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.About IOVA
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors.
IOVA Key Statistics
Stock Snapshot
As of today, Iovance Biotherapeutics(IOVA) shares are valued at $3.88. The company's market cap stands at 1.49B, with a P/E ratio of -3.15.
During the trading session on 2026-02-25, Iovance Biotherapeutics(IOVA) shares reached a daily high of $3.94 and a low of $2.90. At a current price of $3.88, the stock is +33.7% higher than the low and still -1.6% under the high.
Trading activity shows a volume of 69.67M, compared to an average daily volume of 14.09M.
The stock's 52-week range extends from a low of $1.64 to a high of $5.64.
The stock's 52-week range extends from a low of $1.64 to a high of $5.64.
IOVA News
The S&P 500 (SNPINDEX:^GSPC) rose 0.78% to 6,891.04, the Nasdaq Composite (NASDAQINDEX:^IXIC) gained 1.04% to 22,863.68, and the Dow Jones Industrial Average (D...
Iovance Biotherapeutics (NASDAQ:IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL ce...
Iovance Biotherapeutics ( (IOVA) ) has provided an update. On February 24, 2026, Iovance Biotherapeutics reported that 2025 was its first full calendar year of...
Analyst ratings
80%
of 10 ratingsMore IOVA News
Reports Q4 revenue $86.711M, consensus $81.01M. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “Iovance delivere...
Iovance Biotherapeutics (IOVA) announced positive early data from a pilot clinical trial led by Memorial Sloan Kettering Cancer Center, MSKCC, and supported by...
In early February 2026, Iovance Biotherapeutics reported real-world retrospective data showing a best-in-class clinical profile and unprecedented response rates...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.